Addendum: ABT recently launched its adult nutrition line in China. Adult nutrition is a $2B business for ABT globally, representing about 30% of the sales in ABT’s nutrition segment.
Sales of branded-generic drugs in emerging markets—including China—increased 46% YoY to $977M in constant currency; excluding acquisitions, sales of branded generics in emerging markets increased YoY at a low double-digit rate.
ABT retained 2015 non-GAAP EPS guidance of $2.10-2.20.